Drug Trial Radar · NCT01988493
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Aug 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
117
Actual
Start
Jan 6, 2014
Primary completion
Feb 5, 2018
Study completion Dec 3, 2020
Sponsor
- Lead sponsor
- Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- First posted
- Nov 20, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, integrated, Phase 1b/2 trial to determine the recommended Phase 2 dose (RP2D) and to evaluate the efficacy, safety, and pharmacokinetic of MSC2156119J as first-line treatment versus sorafenib in subjects with MET+, Barcelona Clinic Liver Cancer (BCLC) Stage C, systemic treatment naive advanced hepatocellular carcinoma (HCC) and Child-Pugh class A liver function.
Conditions
- Carcinoma, Hepatocellular
Interventions
Tepotinib 300 mgDrug
Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Tepotinib 500 mgDrug
Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Tepotinib 1000 mgDrug
Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
TepotinibDrug
Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
SorafenibDrug
Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Participants Experiencing Dose Limiting ToxicityTime frame: Day 1 to Day 21 of Cycle 1 (each cycle is 21 days)
- Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Baseline up to Day 30 after the last dose of study treatment, assessed up to 94 weeks
- Phase 2: Time to Progression (TTP) Based on Tumor Assessment by an Independent Review Committee (IRC)Time frame: From randomization to date of the observation of radiological progressive disease, assessed up to maximum 3.8 years
Locations
43 sites in 3 countries. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, China
307 Hosptial of PLA
Beijing, Beijing Municipality, China
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA
Fuzhou, Fujian, China
Sun Yat-sen University, Cancer Center
Guangzhou, Guangdong, China
Nanfang Hospital
Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
The Third Xiangya Hospital of Central South University
Changsha, Hu'nan, China
Nanjing Bayi Hospital
Nanjing, Jiangsu, China
Nanjing First Hospital Affiliated to Nanjing Medical University
Nanjing, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
Shanghai Cancer Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Cancer Hospital, Tianjin Medical University
Tianjin, Zhejiang, China
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
Zhejiang, Zhejiang, China
Dong-A University Hospital
Busan, South Korea
Pusan National University Hospital
Busan, South Korea
Keimyung University Dongsan Hospital
Daegu, South Korea
Kyungpook National University Hospital
Daegu, South Korea
National Cancer Center
Goyang-si, South Korea
CHA Bundang Medical Center, CHA University
Seongnam-si, South Korea
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Kyung Hee University Hospital
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Severance Hospital, Yonsei University
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Gangnam Severance Hospital, Yonsei University Health System
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Ajou University Hospital
Suwon, South Korea
Pusan National University Yangsan Hospital
Yangsan, South Korea
Changhua Christian Hospital
Changhua, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
Chi Mei Medical Center, Liou Ying
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.